Tagawa H   Tsuzuki S   Suzuki R   Karnan S   Ota A   Kameoka Y   Suguro M   Matsuo K   Yamaguchi M   Okamoto M   Morishima Y   Nakamura S   Seto M   
Clinical Cancer Research 10(12 I) 4077-4082 2004年7月 [査読有り]
Purpose: Rituximab is an anti-CD20 monoclonal antibody, and it is used to treat B-cell lymphomas. Antibody-dependent cellular cytotoxicity (ADCC) is considered one of the mechanisms through which rituximab exerts its effects. Granulocyte colony-st...
Clinical Cancer Research 10(7) 2482-2490 2004年4月 [査読有り]
Purpose: Recently, we established an ELISA technique for measuring nm23-H1 protein in serum and found that the serum nm23-H1 level is a potential prognostic factor for patients with non-Hodgkin's lymphoma. Experimental Design: We used immunohistoc...
GENES CHROMOSOMES & CANCER 39(1) 77-81 2004年1月 [査読有り]
We recently demonstrated that the prognosis for de novo CD5-positive (CD5(+)) diffuse large-B-cell lymphoma (DLBCL) is markedly worse than that for CD5-negative (CD5(-)) DLBCL. Our findings also suggested that on the basis of its clinical features...
British Journal of Haematology 123(4) 621-630 2003年11月 [査読有り]
We have reported previously that the serum nm23-H1 level is a prognostic factor for non-Hodgkin's lymphoma. In this study, we examined nm23-H1 expression in T- and natural killer (NK)-cell lymphoma in order to evaluate whether lymphoma cells produ...